A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs HMPL-306 (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative disorders; T-cell lymphoma
Focus Adverse reactions
Sponsors Hutchison MediPharma; HUTCHMED

17 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming European Hematology Association (EHA) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
13 Feb 2024 Planned End Date changed from 30 Sep 2023 to 30 Jun 2025.
13 Feb 2024 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com